# Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

> **NCT00131560** · PHASE2 · UNKNOWN · sponsor: **VIRxSYS Corporation** · enrollment: 60 (estimated)

## Conditions studied

- HIV Infection

## Interventions

- **GENETIC:** VRX496-Modified Autologous T cells

## Key facts

- **NCT ID:** NCT00131560
- **Lead sponsor:** VIRxSYS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-07
- **Primary completion:** 2008-11
- **Final completion:** 2023-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131560, "Safety and Efficacy of T Cell Genetic Immunotherapy for HIV". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00131560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*